CapsoVision, Inc 8-K

What Happened

• CapsoVision, Inc. announced a Securities Purchase Agreement completed March 16, 2026, raising approximately $14.0 million in gross proceeds through a private placement. The company issued 2,867,089 shares of common stock at $4.883 per share (a 5% discount to the March 16 closing price). The shares were sold in an unregistered offering under Section 4(a)(2) and Rule 506.
• The company also filed a Registration Rights Agreement committing to file a resale registration statement for the placed shares within 90 days of the closing and to use commercially reasonable efforts to have it declared effective as soon as practicable.
• Separately, CapsoVision issued a press release on March 20, 2026 with preliminary, unaudited financial results for Q4 and full-year 2025 (the 8-K attaches that press release).
• CapsoVision provided program updates: it will discontinue pursuit of its first-generation CapsoCam Colon 510(k) and prioritize a second-generation capsule with improved imaging and AI, expanded a second-arm pivotal study to ~800 U.S. patients (up to 20 sites) and has enrolled over 500 patients; the company expects to submit the second-generation 510(k) in Q3 2026. The company also plans a ~90-patient study for CapsoCam UGI to support a future Breakthrough Device resubmission for early pancreatic cancer detection (study expected to start Q2 2026).

Key Details

• Gross proceeds: ~ $14.0 million from sale of 2,867,089 shares at $4.883 per share (5% discount). Closing: March 16, 2026.
• Registration Rights: Company to file registration statement for resale of the shares within 90 days of closing and use commercially reasonable efforts to get it effective.
• CapsoCam Colon: First-generation 510(k) no longer pursued; second-generation pivotal study expanded to ~800 patients (up to 20 U.S. sites); >500 patients enrolled; expected 510(k) submission in Q3 2026.
• Breakthrough Device / CapsoCam UGI: Initial Breakthrough Device request (filed Nov 6, 2025) was not granted; company will conduct a ~90-patient study (start Q2 2026) and may resubmit.

Why It Matters

• The private placement provides near-term capital for general corporate purposes (sales and marketing, R&D, G&A, working capital, capex), which supports ongoing product development and commercialization efforts without immediate public equity dilution beyond the issuance.
• Registration rights indicate investors will be able to resell the newly issued shares once a registration statement is effective, which can affect future share liquidity and float.
• Strategic shift away from the first-generation CapsoCam Colon toward a second-generation device and an expanded pivotal study likely delays regulatory clearance but aims to improve product performance and regulatory prospects; investors should note the new expected 510(k) timing (Q3 2026) and current enrollment progress (>500 of ~800 patients).
• Breakthrough Device designation for CapsoCam UGI remains pending and will depend on upcoming clinical data; regulatory and commercialization timelines for new indications remain data-driven.
• Investors should review the March 20, 2026 press release (Exhibit 99.1) for the company’s preliminary financial results and monitor subsequent filings for the registration statement, full audited results, and additional clinical/regulatory updates.